Human Sulfatase 2 inhibits in vivo tumor growth of MDA-MB-231 human breast cancer xenografts

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Peterson, Sarah M ^a   Iskenderian, Andrea ^b   Cook, Lynette ^b   Romashko, Alla ^b   Tobin, Kristen ^a   Jones, Michael ^a   Norton, Angela ^b   Gómez Yafal, Alicia ^b   Heartlein, Michael W ^b   Concino, Michael F ^b   Liaw, Lucy ^a   Martini, Paolo G V ^b  

^a Maine Medical Center Research Institute   (United States)

^b SHIRE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE; RECOMBINANT SULFATASE 2; SULFATASE; SULFATASE 1; SULFATASE 2; UNCLASSIFIED DRUG; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 3; RECOMBINANT PROTEIN; SULF2 PROTEIN, HUMAN; SULFOTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER REGRESSION; CANCER SIZE; CELL PROLIFERATION; CELL STRAIN MDA MB 231; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; WILD TYPE; ANIMAL; BREAST TUMOR; CELL ADHESION; CELL MOTION; DRUG SCREENING; ENZYMOLOGY; GENETICS; METABOLISM; NUDE MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENZYME ACTIVATION; FEMALE; HUMANS; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 3; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFOTRANSFERASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955488762     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-427     Document Type: Article

References (24)

1. Goldman M, O'Hair K. Women's health, breast health: a review of the gynecologic effects of breast cancer. Obstet Gynecol Surv 2009, 64(7):469-480. quiz 499, 10.1097/OGX.0b013e3181a713f1, 19545455.
2. Frese MA, Milz F, Dick M, Lamanna WC, Dierks T. Characterization of the human sulfatase Sulf1 and its high affinity heparin/heparan sulfate interaction domain. J Biol Chem 2009, 284(41):28033-28044. 10.1074/jbc.M109.035808, 19666466.
3. Liu D, Shriver Z, Venkataraman G, El Shabrawi Y, Sasisekharan R. Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc Natl Acad Sci USA 2002, 99(2):568-573. 10.1073/pnas.012578299, 117346, 11805315.
4. Dai Y, Yang Y, MacLeod V, Yue X, Rapraeger AC, Shriver Z, Venkataraman G, Sasisekharan R, Sanderson RD. HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J Biol Chem 2005, 280(48):40066-40073. 10.1074/jbc.M508136200, 16192265.
5. Chau BN, Diaz RL, Saunders MA, Cheng C, Chang AN, Warrener P, Bradshaw J, Linsley PS, Cleary MA. Identification of SULF2 as a novel transcriptional target of p53 by use of integrated genomic analyses. Cancer Res 2009, 69(4):1368-1374. 10.1158/0008-5472.CAN-08-2742, 19190338.
6. Morimoto-Tomita M, Uchimura K, Bistrup A, Lum DH, Egeblad M, Boudreau N, Werb Z, Rosen SD. Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. Neoplasia 2005, 7(11):1001-1010. 10.1593/neo.05496, 1502017, 16331886.
7. Lai J, Chien J, Staub J, Avula R, Greene EL, Matthews TA, Smith DI, Kaufmann SH, Roberts LR, Shridhar V. Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem 2003, 278(25):23107-23117. 10.1074/jbc.M302203200, 12686563.
8. Narita K, Staub J, Chien J, Meyer K, Bauer M, Friedl A, Ramakrishnan S, Shridhar V. HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. Cancer Res 2006, 66(12):6025-6032. 10.1158/0008-5472.CAN-05-3582, 16778174.
9. Holst CR, Bou-Reslan H, Gore BB, Wong K, Grant D, Chalasani S, Carano RA, Frantz GD, Tessier-Lavigne M, Bolon B, et al. Secreted sulfatases Sulf1 and Sulf2 have overlapping yet essential roles in mouse neonatal survival. PLoS One 2007, 2(6):e575. 10.1371/journal.pone.0000575, 1892809, 17593974.
10. Lai JP, Chien JR, Moser DR, Staub JK, Aderca I, Montoya DP, Matthews TA, Nagorney DM, Cunningham JM, Smith DI, et al. hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology 2004, 126(1):231-248. 10.1053/j.gastro.2003.09.043, 14699503.
11. Hampton OA, Den Hollander P, Miller CA, Delgado DA, Li J, Coarfa C, Harris RA, Richards S, Scherer SE, Muzny DM, et al. A sequence-level map of chromosomal breakpoints in the MCF-7 breast cancer cell line yields insights into the evolution of a cancer genome. Genome Res 2009, 19(2):167-177. 10.1101/gr.080259.108, 2652200, 19056696.
12. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989, 24(3):148-154. 10.1007/BF00300234, 2544306.
13. ImageJ. , http://rsb.info.nih.gov/ij
14. Miki Y, Suzuki T, Sasano H. Intracrinology of sex steroids in ductal carcinoma in situ (DCIS) of human breast: comparison to invasive ductal carcinoma (IDC) and non-neoplastic breast. J Steroid Biochem Mol Biol 2009, 114(1-2):68-71. 10.1016/j.jsbmb.2008.12.021, 19444935.
15. Banerjee S, Dowsett M, Ashworth A, Martin LA. Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 2007, 4(9):536-550. 10.1038/ncponc0905, 17728712.
16. Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S, Rosen SD. Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J Biol Chem 2002, 277(51):49175-49185. 10.1074/jbc.M205131200, 2779716, 12368295.
17. Gangarosa LM, Sizemore N, Graves-Deal R, Oldham SM, Der CJ, Coffey RJ. A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells. J Biol Chem 1997, 272(30):18926-18931. 10.1074/jbc.272.30.18926, 9228072.
18. Fraker LD, Halter SA, Forbes JT. Growth inhibition by retinol of a human breast carcinoma cell line in vitro and in athymic mice. Cancer Res 1984, 44(12 Pt 1):5757-5763.
19. Wang J, Ou ZL, Hou YF, Luo JM, Shen ZZ, Ding J, Shao ZM. Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential. Oncogene 2006, 25(54):7201-7211. 10.1038/sj.onc.1209703, 16785997.
20. Ai X, Do AT, Lozynska O, Kusche-Gullberg M, Lindahl U, Emerson CP. QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling. J Cell Biol 2003, 162(2):341-351. 10.1083/jcb.200212083, 2172803, 12860968.
21. Uchimura K, Morimoto-Tomita M, Bistrup A, Li J, Lyon M, Gallagher J, Werb Z, Rosen SD. HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1. BMC Biochem 2006, 7:2. 10.1186/1471-2091-7-2, 1386684, 16417632.
22. Hui L, Zheng Y, Yan Y, Bargonetti J, Foster DA. Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. Oncogene 2006, 25(55):7305-7310. 10.1038/sj.onc.1209735, 16785993.
23. Lim LY, Vidnovic N, Ellisen LW, Leong CO. Mutant p53 mediates survival of breast cancer cells. Br J Cancer 2009, 101:1606-1612. 10.1038/sj.bjc.6605335, 19773755.
24. Ai X, Do AT, Kusche-Gullberg M, Lindahl U, Lu K, Emerson CP. Substrate specificity and domain functions of extracellular heparan sulfate 6-O-endosulfatases, QSulf1 and QSulf2. J Biol Chem 2006, 281(8):4969-4976. 10.1074/jbc.M511902200, 16377625.